Hypertension: key endpoint results by drug
The key endpoints of Hypertension trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Hypertension page.
Seated SBP, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aprocitentan | -15.3 | -11.5 | −3.8 | 12.5 mg · wk 4 · n 243 | NCT03541174 Phase 3, primary |
| Baxdrostat | -15.7 | -5.8 | −9.9 | 2 mg · wk 12 · n 266 | NCT06034743 Phase 3, primary |
| Sacubitril/valsartan | -20.2 | -13.2 (Olmesartan) | — | 400 mg · wk 8 · n 385 | NCT01599104 Phase 3, primary |
| Zilebesiran | -11.1 | -0.6 | −10.5 | 300 mg Q6M · wk 24 · n 68 | NCT04936035 Phase 2, secondary |
Drugs checked with no result here: 10 not posted, 5 trial running, 6 not reported.
24-hour ambulatory SBP, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Baxdrostat | -16.6 | -2.6 | −14 | 2 mg · wk 12 · n 89 | NCT06168409 Phase 3, primary |
| Sacubitril/valsartan | -4.3 | -1.0 (Olmesartan) | — | 200 mg · wk 8 · n 167 | NCT01876368 Phase 3, primary |
| Zilebesiran | -8.9 | 6.8 | −15.7 | 600 mg Q6M · wk 12 · n 65 | NCT04936035 Phase 2, primary |
Drugs checked with no result here: 10 not posted, 6 trial running, 6 not reported.
Seated DBP, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aprocitentan | -10.4 | -6.5 | −3.9 | 12.5 mg · wk 4 · n 243 | NCT03541174 Phase 3, secondary |
| Baxdrostat | -6.9 | -3 | −3.9 | 2 mg · wk 12 · n 266 | NCT06034743 Phase 3, secondary |
| Sacubitril/valsartan | -8.8 | -6.9 (Olmesartan) | — | 400 mg · wk 8 · n 469 | NCT01785472 Phase 3, secondary |
| Zilebesiran | -6.8 | -1.2 | −5.6 | 300 mg Q6M · wk 24 · n 68 | NCT04936035 Phase 2, secondary |
Drugs checked with no result here: 10 not posted, 5 trial running, 6 not reported.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 25 approved or late-stage drugs with a featured trial in Hypertension were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.